Ernexa Therapeutics Inc. Common Stock
ERNAErnexa Therapeutics Inc. (ERNA) is a biotech company focused on developing innovative therapies for neurodegenerative diseases. The company leverages advanced technologies to identify and target novel pathways involved in conditions such as Alzheimer’s and Parkinson’s disease, aiming to address unmet medical needs in these areas.
Company News
Ernexa Therapeutics (NASDAQ: ERNA) announced the pricing of a $10.5 million public offering of 21 million shares at $0.50 per share, along with warrants to purchase up to 21 million shares at $0.68 exercise price. The company plans to use proceeds to advance its cell therapy development programs, particularly ERNA-101 for ovarian cancer treatment...
Eterna Therapeutics to Present at ASGCT on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line
Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board
Eterna Therapeutics (ERNA) Announces the Appointment of Peter Cicala, JD, to its Board of Directors
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced that Eterna’s Board of Directors granted a non-qualified ...
